Mark W Tenforde

Mark W Tenforde publications per year

Mark W Tenforde publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark W Tenforde sits on this spectrum.

Mark W Tenforde D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark W Tenforde sits on this spectrum.

Best Publications

• Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.

  Leora R. Feldstein;Leora R. Feldstein;Erica B. Rose;Erica B. Rose;Steven M. Horwitz;Jennifer P. Collins

  2867
  Citations

• Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19.

  Leora R. Feldstein;Leora R. Feldstein;Mark W. Tenforde;Kevin G. Friedman;Margaret Newhams

  811
  Citations

• Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

  Unknown

  677
  Citations

• Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.

  Mark W Tenforde;Wesley H Self;Katherine Adams;Manjusha Gaglani

  657
  Citations

• Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.

  Wesley H. Self;Mark W. Tenforde;Jillian P. Rhoads;Manjusha Gaglani;Manjusha Gaglani

  425
  Citations

• Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome.

  Kerri L. Larovere;Becky J. Riggs;Tina Y. Poussaint;Cameron C. Young

  391
  Citations

• Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021.

  Mark W. Tenforde;Samantha M. Olson;Wesley H. Self;H. Keipp Talbot

  278
  Citations

• Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.

  Mark W. Tenforde;Wesley H. Self;Eric A. Naioti;Adit A. Ginde

  223
  Citations

• Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network - 13 Academic Medical Centers, April-June 2020.

  Wesley H. Self;Mark W. Tenforde;William B. Stubblefield;Leora R. Feldstein

  223
  Citations

• Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

  Unknown

  208
  Citations

• Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022

  Unknown

  185
  Citations

• Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

  Unknown

  183
  Citations

• Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

  Unknown

  164
  Citations

• Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States.

  Mark W Tenforde;Manish M Patel;Adit A Ginde;David J Douin

  149
  Citations

• Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network-12 States, April-August 2020

  Wesley H Self;Mark W Tenforde;William B Stubblefield;Leora R Feldstein

  144
  Citations

• Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

  Unknown

  138
  Citations

• Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

  Unknown

  130
  Citations

• Effect of antigenic drift on influenza vaccine effectiveness in the United States - 2019-2020.

  Mark W Tenforde;Rebecca J Garten Kondor;Jessie R Chung;Richard K Zimmerman

  122
  Citations

• Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines.

  Joseph A Lewnard;Manish M Patel;Nicholas P Jewell;Nicholas P Jewell;Jennifer R Verani

  120
  Citations

• Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19-Nashville, Tennessee.

  William B Stubblefield;H Keipp Talbot;Leora R Feldstein;Mark W Tenforde

  115
  Citations